WEBULL
News
SLRX
0.6541
+0.82%
0.0053
Weekly Report: what happened at SLRX last week (1222-1226)?
Weekly Report · 12/29/2025 09:32
Weekly Report: what happened at SLRX last week (1215-1219)?
Weekly Report · 12/22/2025 09:32
Salarius Pharmaceuticals Adjourns Annual Meeting Over Quorum Shortfall
TipRanks · 12/19/2025 22:06
Press Release: Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Dow Jones · 12/19/2025 16:12
Salarius announces planned corporate name change to Decoy Therapeutics
TipRanks · 12/18/2025 12:56
Salarius Pharmaceuticals To Rebrand As Decoy Therapeutics Following Combination, Changes NASDAQ Ticker Symbol To DCOY
Benzinga · 12/18/2025 12:52
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics
Reuters · 12/18/2025 12:50
SALARIUS PHARMACEUTICALS INC - TO CHANGE NAME TO DECOY THERAPEUTICS AND TICKER TO DCOY
Reuters · 12/18/2025 12:50
SALARIUS PHARMACEUTICALS ANNOUNCES PLANNED CORPORATE NAME AND TICKER SYMBOL CHANGE TO DECOY THERAPEUTICS, REFLECTING STRATEGIC PIVOT TO NEXT-GENERATION ANTIVIRAL AND PEPTIDE-CONJUGATE PLATFORM
Reuters · 12/18/2025 12:50
Weekly Report: what happened at SLRX last week (1208-1212)?
Weekly Report · 12/15/2025 09:35
Weekly Report: what happened at SLRX last week (1201-1205)?
Weekly Report · 12/08/2025 09:34
Salarius Pharmaceuticals, Texas Biomed collaborate on Avian Flu study
TipRanks · 12/01/2025 13:16
Salarius' Decoy Therapeutics Announces Collaboration To Conduct In Vitro Testing Of Decoy's Peptide Conjugate Fusion Inhibitors Across Several Influenza Strains Including H5N1 Avian Flu
Benzinga · 12/01/2025 13:03
SALARIUS PHARMACEUTICALS TO COLLABORATE WITH TEXAS BIOMEDICAL RESEARCH INSTITUTE ON AVIAN FLU STUDY
Reuters · 12/01/2025 13:00
Weekly Report: what happened at SLRX last week (1124-1128)?
Weekly Report · 12/01/2025 09:32
Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares
Reuters · 11/24/2025 22:08
Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Scientific Officer Barbara Louise Hibner
Reuters · 11/24/2025 16:25
Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Business Officer Peter Klaus Marschel
Reuters · 11/24/2025 16:24
Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for CEO Frederick II Pierce
Reuters · 11/24/2025 16:23
Weekly Report: what happened at SLRX last week (1117-1121)?
Weekly Report · 11/24/2025 09:34
More
Webull provides a variety of real-time SLRX stock news. You can receive the latest news about Salarius Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. It is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.